Predicting tuberculosis risk – Authors’ reply

The Lancet

Volumn 388, Issue 10057, 2016, Pages 2233-2234

  Zak, Daniel ^a   Scriba, Thomas J ^b   Hatherill, Mark ^b   Penn Nicholson, Adam ^b   Hanekom, Willem ^b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAPENTINE; RNA;

HUMAN; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LETTER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUBERCULOSIS;

EID: 84994589965     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31653-1     Document Type: Letter

References (3)

1. 1 Zak, DE, Penn-Nicholson, A, Scriba, TJ, et al., for the ACS and GC6–74 cohort study groups. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387 (2016), 2312–2322.
2. 2 Seshadri, P, Denkinger, C, Draft target product profile: test for progression of tuberculosis infection. http://www.finddx.org/wp-content/uploads/2016/05/TPP-LTBIprogression.pdf (accessed July 16, 2016).
3. 3 Perez-Velez, CM, Marais, BJ, Tuberculosis in children. N Engl J Med 367 (2012), 348–361.